An estimated 39 million Americans live with migraine, making it one of the most common neurological conditions and a leading cause of disability in working-age adults worldwide. The condition is far more than a bad headache – migraine is a complex neurological disorder involving multiple phases, sensory changes, and often debilitating symptoms beyond head pain. Roughly the last decade produced a genuine revolution in migraine care: the first medications designed specifically to prevent migraine, plus new acute options that work without the vascular cautions of older drugs. As of 2026, that expanded toolkit continues to reshape treatment for millions of patients.
This guide covers migraine phases, types, triggers, and current acute and preventive treatment options. It is educational and not a substitute for individualized medical advice. For broader context, see our medical conditions resource hub.
When to Seek Emergency Care
Call 911 or go to the nearest emergency room for a sudden, severe “thunderclap” headache that peaks within seconds to minutes, or “the worst headache of your life.” Also seek emergency evaluation for a headache with fever and a stiff neck, a headache accompanied by confusion, weakness, numbness, trouble speaking, or vision loss, a headache after a head injury, or a headache with fainting or a seizure. These features can signal a stroke, a brain hemorrhage, meningitis, or another serious condition – not a migraine. A new or different headache pattern that first appears after age 50, or a headache that steadily worsens over days, also warrants prompt medical evaluation rather than watchful waiting.
What Migraine Is
Migraine is a primary headache disorder, meaning it is the disease itself rather than a symptom of another condition. It involves recurrent moderate to severe headaches with characteristic features: a pulsating or throbbing quality, an often one-sided location, worsening with routine physical activity, and accompanying symptoms such as nausea, vomiting, or heightened sensitivity to light and sound.
According to the National Institute of Neurological Disorders and Stroke, migraine affects a large share of U.S. adults, and it is roughly two to three times more common in women than in men. Onset typically occurs in adolescence or young adulthood, with peak prevalence in the 30s and 40s. Because migraine tends to run in families, a personal and family history is an important part of assessment.
The Phases of a Migraine Attack
A migraine attack can unfold in up to four distinct phases, though not everyone experiences all four, and the pattern can vary from attack to attack.
Prodrome begins hours to days before the headache and may include mood changes, food cravings, neck stiffness, frequent yawning, difficulty concentrating, and increased thirst or urination. Many people learn to recognize their personal prodrome and use it as an early cue to act.
Aura affects roughly a quarter to a third of people with migraine. Most commonly it is visual – zigzag lines, blind spots, or shimmering, expanding “scintillating” patterns – but aura can also include sensory symptoms such as tingling spreading across one side of the body, difficulty speaking, or, rarely, motor weakness (hemiplegic migraine). Aura symptoms usually develop gradually, last from a few minutes up to an hour, and most often precede but sometimes overlap with the headache.
Headache typically lasts 4 to 72 hours when untreated or inadequately treated. Pain is moderate to severe, often throbbing and one-sided, and tends to worsen with movement. Photophobia (light sensitivity), phonophobia (sound sensitivity), osmophobia (sensitivity to smells), nausea, and vomiting frequently accompany the pain. Postdrome, sometimes called the “migraine hangover,” follows the headache and can bring fatigue, cognitive fog, and mood changes lasting hours to a day.
Migraine Types
The two most common types are migraine without aura (the majority of cases) and migraine with aura. Chronic migraine is defined as headache on 15 or more days per month, with at least 8 of those days meeting migraine criteria, for at least three months. Chronic migraine affects a small percentage of the population but often causes substantial disability and is a distinct treatment target.
Less common variants include hemiplegic migraine (with temporary motor weakness), retinal migraine (visual disturbance in one eye), vestibular migraine (dizziness or vertigo as a primary feature), and migraine with brainstem aura. Per Mayo Clinic, accurately identifying the subtype can influence which treatments are safest and most effective, which is one reason a clinical evaluation matters.
Common Triggers
Triggers vary from person to person, but frequently reported ones include hormonal changes (menstrual migraine is common among women with migraine), specific foods and additives (aged cheeses, processed meats with nitrates, and for some people MSG or alcohol – red wine in particular), caffeine (both excess intake and withdrawal), stress or the “let-down” after stress, changes in sleep (too little or too much), skipping meals, dehydration, weather changes, bright or flickering light and other strong sensory stimuli, and certain medications.
Keeping a headache diary – noting timing, possible triggers, sleep, meals, and menstrual cycle – helps many people identify personal patterns and reduce attack frequency. That said, trigger avoidance has limits: over-restriction can become its own burden, triggers often need to combine to provoke an attack, and many attacks have no identifiable trigger at all.
Causes and Risk Factors
Migraine has a substantial genetic component, and multiple genes appear to influence susceptibility through effects on cortical excitability, vascular regulation, and pain processing. The trigeminovascular system and CGRP (calcitonin gene-related peptide) signaling are central to migraine biology – an understanding that directly informed the newer, migraine-specific treatments.
Risk factors include family history, female sex (with a marked increase after puberty), and coexisting conditions such as depression and anxiety disorders, sleep disorders, and obesity. Importantly, migraine with aura is associated with a modestly elevated stroke risk, which is higher in women who also smoke or use estrogen-containing contraceptives – a reason to discuss contraception choices with a clinician if you have aura.
Diagnosis
Migraine is diagnosed clinically, based on the pattern and features of attacks rather than a specific test. The ICHD-3 (International Classification of Headache Disorders, 3rd edition) criteria specify features such as attack duration, pain characteristics, and associated symptoms. Brain imaging is not required for typical migraine, but it may be ordered when “red flags” suggest a secondary cause.
Red flags that prompt imaging or urgent evaluation include a sudden, severe onset, a new headache after age 50, a weakened immune system, a history of cancer, focal neurologic deficits, fever, or a headache that is progressively worsening. Clinicians sometimes use the “SNNOOP10” set of warning features to help identify headaches that need further workup.
Acute (Abortive) Treatment
Acute treatment aims to stop an attack once it starts, and treating early – while pain is still mild – generally improves the response. This section describes drug classes only; it does not provide dosing. Your clinician and pharmacist determine the right medication, dose, and precautions for you.
For mild to moderate attacks, NSAIDs (such as ibuprofen or naproxen) and acetaminophen are often effective, and a combination product containing acetaminophen, aspirin, and caffeine is FDA-approved for migraine. Triptans (for example sumatriptan, rizatriptan, and eletriptan) have been first-line prescription acute medications since the 1990s and help many people, but they are generally avoided in people with cardiovascular disease, prior stroke, or uncontrolled high blood pressure. Generic triptans are widely available and typically inexpensive, though cash prices vary – comparing pharmacy and discount-program prices is worthwhile.
Newer options avoid the vascular cautions of triptans. Gepants (small-molecule CGRP receptor antagonists such as ubrogepant and rimegepant, plus a zavegepant nasal spray) offer acute relief without triptan-style cardiovascular contraindications. Ditans (lasmiditan) act on serotonin 5-HT1F receptors and provide another non-vascular option, though they can cause drowsiness and carry driving precautions. Per Cleveland Clinic, anti-nausea medications such as metoclopramide can ease nausea and may have a direct anti-migraine effect. A clinician can match the option to your other conditions and medications.
Medication-Overuse (Rebound) Headache
Using acute headache medications too frequently can paradoxically drive more headaches – a pattern called medication-overuse headache (MOH), or rebound headache. As a general guide, the risk rises with triptans, ergots, opioids, or combination pain relievers used on about 10 or more days per month, or simple analgesics used on about 15 or more days per month. This is a major reason clinicians emphasize limiting acute-medication days and starting preventive treatment when attacks are frequent. Treating MOH usually involves a structured plan to reduce the overused medication under medical supervision, alongside starting a preventive therapy – not something to attempt with a copy-and-paste schedule from the internet.
Preventive Treatment
Preventive (prophylactic) medication is generally considered when attacks occur on roughly 4 or more days per month, when attacks are especially severe or disabling, when acute medications are ineffective or contraindicated, or when there is a risk of medication overuse. The goal is to reduce attack frequency, severity, and duration.
Longer-established preventive options include beta-blockers (such as propranolol and metoprolol), certain anti-seizure medications (topiramate, valproate), tricyclic antidepressants (amitriptyline, nortriptyline), and venlafaxine. These are inexpensive and generic but can have side effects that affect adherence, and some are unsafe in pregnancy – decisions belong with your clinician.
CGRP-targeted preventive therapies have reshaped migraine prevention. Monoclonal antibodies against CGRP or its receptor (erenumab, fremanezumab, galcanezumab, and eptinezumab), given by injection or infusion on a monthly or quarterly schedule, meaningfully cut monthly migraine days for many people and are generally well tolerated. Oral CGRP receptor antagonists (atogepant and rimegepant) provide additional once-daily or every-other-day preventive options. List prices for these newer drugs are high – often in the hundreds to around a thousand dollars per month – but manufacturer copay-assistance programs and insurance coverage frequently reduce out-of-pocket costs substantially; verify specifics with your plan.
OnabotulinumtoxinA (Botox) is FDA-approved specifically for chronic migraine and is given as a series of small injections around the head and neck roughly every 12 weeks by a trained clinician. It is not used for episodic migraine. Out-of-pocket cost varies widely by setting and coverage, and insurance approval generally requires documented chronic migraine.
Lifestyle and Non-Drug Approaches
A regular sleep schedule, consistent meal timing, steady hydration, regular aerobic exercise, and stress management each have evidence for reducing migraine frequency. Some supplements – including magnesium, riboflavin (vitamin B2), and coenzyme Q10 – have modest supporting evidence for prevention; discuss appropriate forms and amounts with your clinician or pharmacist rather than self-prescribing, since supplements can interact with other conditions and medications.
Cognitive behavioral therapy, relaxation training, and biofeedback have evidence-based roles, especially when stress or comorbid depression and anxiety are contributing. Prescription and over-the-counter neuromodulation devices – such as transcutaneous trigeminal nerve stimulation, external vagus nerve stimulation, and remote electrical neuromodulation – offer non-drug options that can be used alone or alongside medication.
When to See a Doctor
Recurrent moderate to severe headaches that interfere with work, school, or daily life warrant evaluation. Primary care clinicians can diagnose and treat typical migraine; neurologists – particularly headache specialists – handle refractory cases, chronic migraine, and complex variants. The American Migraine Foundation, affiliated with the American Headache Society, maintains a searchable resource to help find headache specialists. Telehealth has expanded access to migraine care, which can be especially helpful where in-person specialists are scarce.
Frequently Asked Questions
What is the difference between migraine and a regular headache?
Migraine is a specific neurological disorder with characteristic features – moderate to severe pain that is often one-sided and pulsating, accompanied by nausea or sensitivity to light and sound, and typically lasting 4 to 72 hours. Tension-type headache is usually felt on both sides, described as pressing or tightening rather than throbbing, and is not associated with severe nausea or worsening with routine movement.
Can migraine cause permanent damage?
Most migraine attacks do not cause lasting brain damage. However, migraine with aura is associated with a modestly increased stroke risk and with small white-matter changes on MRI, and chronic migraine can produce significant, ongoing disability. Effective treatment reduces both immediate suffering and, potentially, some longer-term risk. Any sudden or severe change in your usual pattern should be evaluated promptly.
Are CGRP drugs safe long term?
CGRP-targeted drugs have been in use since 2018, and safety data have continued to accumulate. Short- and medium-term data suggest good tolerability with low rates of serious adverse effects, and longer-term cardiovascular and immune safety remain under study without major warning signals to date. As with any medication, your clinician weighs benefits and risks for your specific situation, including pregnancy plans.
Can migraine go away over time?
Migraine often follows a fluctuating course across decades. Many people have fewer attacks after age 50, and some women improve after menopause while others worsen during perimenopause. Effective preventive treatment can produce sustained reductions in frequency, sometimes allowing a carefully supervised taper later on.
The Bottom Line
Migraine is a common, treatable neurological condition, and the treatment toolkit has expanded dramatically with CGRP-targeted therapies and other newer options. Good management pairs acute treatment for individual attacks with preventive strategies when attacks are frequent, guards against medication overuse, and layers in evidence-based lifestyle and behavioral approaches. If migraine is interfering with your work, school, or daily life, an evaluation by a primary care clinician or headache specialist can open up far more effective options than over-the-counter pain relief alone.
TL;DR & Medical Disclaimer
TL;DR: Migraine is a phased neurological disorder, not just a bad headache. Acute treatments include NSAIDs, triptans, gepants, and ditans; preventives include CGRP monoclonal antibodies, oral gepants, Botox, and older drugs such as beta-blockers and topiramate. Limit acute-medication days to avoid rebound headache. A sudden “thunderclap” or “worst headache of your life,” or a headache with fever, stiff neck, confusion, weakness, vision loss, or after a head injury, is an emergency – call 911.
Disclaimer: This article is for general education only and is not medical advice, and it intentionally does not include drug dosing. It cannot replace diagnosis, treatment, or dosing decisions from a qualified clinician who knows your history. Always consult your physician or pharmacist before starting, stopping, or changing any medication or supplement.
Sources
- Mayo Clinic – Migraine: Symptoms and causes
- American Headache Society / American Migraine Foundation – patient and clinician resources
- Cleveland Clinic – Migraine Headaches
- National Institute of Neurological Disorders and Stroke (NIH) – Migraine
- International Classification of Headache Disorders, 3rd edition (ICHD-3)